Pharma BD Deal Intelligence
Agios Licenses Cevidoplenib in $165M SYK Deal. Agios Pharmaceuticals secured an exclusive global license to cevidoplenib from South Korea's Oscotec for a…
Agios Enters Global License Agreement For Cevidoplenib. Agios Pharmaceuticals entered an exclusive global license agreement with Oscotec to develop and…
Eyes on Asia: Olix, Agios, Eli Lilly. Agios licensed global rights to cevidoplenib from South Korea's Oscotec for up to $165 million, targeting immune…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
On June 1, 2026, Agios Pharmaceuticals entered an exclusive global license agreement with South Korea's Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK (spleen tyrosine kinase) inhibitor, with an initial focus on immune thrombocytopenia (ITP), a rare autoimmune bleeding disorder. Oscotec receives $25 million upfront and is eligible for up to $140 million in development and regulatory milestones across up to three indications in the U.S. and Europe, plus commercial milestones and tiered royalties ranging from high-single-digit to mid-teen percentages on net sales. Oscotec retains an option to commercialize cevidoplenib in South Korea following Phase 3 results.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Agios Pharmaceuticals Inc. / Oscotec Inc. (this deal) | 2026 | $165M | 63 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2026 deals · Hematology deals